Navigation Links
MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
Date:10/20/2010

ROCKVILLE, Md. and INDIANAPOLIS, Oct. 20 /PRNewswire-FirstCall/ -- MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the Protege Data Monitoring Committee (DMC), composed of independent experts in the fields of diabetes and biostatistics, has completed a planned analysis of one-year safety and efficacy data of the Protege Phase 3 clinical trial of teplizumab, an investigational biologic under development for the treatment of individuals with recent-onset type 1 diabetes.

The DMC concluded that the primary efficacy endpoint of the study, a composite of a patient's total daily insulin usage and HbA1c level at 12 months, was not met. The DMC, noting that all administration of experimental drug had been completed, commented that appropriate safety monitoring is warranted. No unanticipated safety issues were identified in the DMC's review.

"We will comply with the DMC's recommendations," said Scott Koenig, M.D., Ph.D., President and Chief Executive Officer, MacroGenics. "We remain committed to discovering and developing novel biologics for the treatment of autoimmune disorders like type 1 diabetes."

Following careful evaluation of the DMC's recommendations for Protege, based on the lack of efficacy, the companies have decided to suspend further enrollment and dosing of patients in two other ongoing clinical trials of teplizumab in type 1 diabetes: the Protege Encore Trial, a second Phase 3 trial of the same design as Protege, and the SUBCUE trial, a Phase 1b trial that is exploring the subcutaneous administration in patients with type 1 diabetes.

"The failure to meet the primary endpoint is obviously disappointing for the millions of people who live with and treat type 1 diabetes," said Gwen Krivi, Vice President, Product Development, Lilly Diabetes. "Lilly and MacroGenics will be considering all options for teplizumab in type 1 di
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
3. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
4. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
5. Lilly and Glenmark Pharmaceuticals Announce License Agreement
6. Lilly Receives NCQA Design Certification for Depression Care Management Program
7. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
8. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
9. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
10. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
11. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 The Chinese wound care market ... rise in the incidence of lifestyle diseases, coupled with ... affordability of better quality of wound care products provide ... coverage of public health insurance schemes and increased reimbursement ... Based on the findings of primary and secondary researches, ...
(Date:9/30/2014)... , N.J. and NEW BRUNSWICK, N.J., Sept. 30, 2014 /PRNewswire-USNewswire/ ... that allows Kessler Foundation and New Jersey Health ... research, education and patient care programs has been ... chief executive officer of Kessler Foundation and ... Health Foundation. "The experience of New ...
(Date:9/30/2014)... 2014 BioStructures, LLC has been awarded ... Tissue Banks (AATB), it was announced today by ... Accreditation follows an intensive nine-month process, including ... inspector.  It establishes that the level of medical, ... or exceeds the standards set by the AATB.  ...
Breaking Medicine Technology:China Wound Care Market 2China Wound Care Market 3Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2Biostructures, LLC Earns AATB Accreditation 2
... 13 Rcadia Medical Imaging today announced that ... of coronary CT angiography (cCTA) will be featured in ... scientific meeting of the Society of Cardiovascular Computed Tomography ... .  SCCT is the international professional society representing physicians, ...
... FOREST, Ill. , July 13 ... leading provider of clinical information and medication delivery technologies, ... clinical surveillance system helped clinicians at Memorial ... an increase in infection-control interventions. The hospital, which used ...
Cached Medicine Technology:Rcadia Announces Five COR Analyzer® Studies to be Presented at SCCT Annual Scientific Meeting 2Rcadia Announces Five COR Analyzer® Studies to be Presented at SCCT Annual Scientific Meeting 3Hospira TheraDoc(TM) Infection Control Assistant(TM) Documents Interventions to Help Hospital Reduce Catheter-Related Infections 2Hospira TheraDoc(TM) Infection Control Assistant(TM) Documents Interventions to Help Hospital Reduce Catheter-Related Infections 3Hospira TheraDoc(TM) Infection Control Assistant(TM) Documents Interventions to Help Hospital Reduce Catheter-Related Infections 4Hospira TheraDoc(TM) Infection Control Assistant(TM) Documents Interventions to Help Hospital Reduce Catheter-Related Infections 5Hospira TheraDoc(TM) Infection Control Assistant(TM) Documents Interventions to Help Hospital Reduce Catheter-Related Infections 6
(Date:9/30/2014)... 2014 Integrated Medicine Alliance , ... another new medical specialty practice through a unique partnership ... will be located within the company’s Shrewsbury location and ... Isaac Tawfik of American Heart Center, P.C., a highly ... will offer Integrated Medicine Alliance patients top notch cardiovascular ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Glycodrive ... Star Nutraceuticals designed to help maximize lean, strong muscle ... the body’s absorption of glucose has caught the attention ... “The main purpose behind Glycodrive is to help the ... muscle,” reports Michaels. “Carbs are essential in the muscle-building ...
(Date:9/30/2014)... September 30, 2014 VisitandCare.com ... Turkey has gone up more than 79 percent in ... tourism company also reported total revenue tripled for its ... The company’s professional strategy has allowed them to partner ... designed for patient comfort and privacy — with state-of-the-art ...
(Date:9/30/2014)... Washington, DC (PRWEB) September 30, 2014 A ... the world to combat an epidemic that, left unchecked, could ... no, they are not headed to Africa. John Rogers, the ... headed to North Korea to fight a disease most think ... the US some 80 years ago is on the comeback ...
(Date:9/30/2014)... Levothyroxine is considered the gold standard therapy for ... of therapies for the condition including combining levothyroxine ... say a team of investigators.,1Their analysis, published as a ... finds insufficient consistent data exist to recommend a change ... under various trade names, such as Synthroid as ...
Breaking Medicine News(10 mins):Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2Health News:New guidelines for treatment of hypothyroidism endorse current therapy 2
... March 27 /PRNewswire/-- CVCTA Education, the leader in,physician ... new education,program that helps physicians reduce the radiation ... properly performed, radiation doses during CTA,are in the ... has been attributed,to creating a health risk. However, ...
... The following statement was,issued today by the law firm ... hereby given that a class action lawsuit was filed in ... behalf,of all purchasers of securities of NeuroMetrix Inc. (Nasdaq: ... March 6,2007, inclusive (the "Class Period")., If you wish ...
... the 37th Annual Meeting of the American Association for ... Hotel in Dallas, several eminent scientists will be part ... and Friday mornings, the meeting will feature a Distinguished ... All lectures will occur in the Stemmons Ballroom at ...
... Following is a summary of the keynote presentations, symposia, ... of the American Association for Dental Research, convening April ... Presentations , Wednesday, April 2 , ... from the Analysis of Clinical Failures,Susanne Scherrer (University of ...
... however most believed,they were not pregnant at the ... with each case., HARRISBURG, Pa., March 27 ... 90 cases reported to the,Pennsylvania Patient Safety Authority ... were not pregnant, according to analysis published in ...
... Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today that ... Drugs: The Future of Molecular Diagnostics Roundtable,Conference" in New ... Eastern,Time. The presentation is scheduled to be webcast live ... information section of Gen-Probe,s website,at http://www.gen-probe.com . The ...
Cached Medicine News:Health News:CVCTA Education Announces New LOW DOSE Initiative for CT Angiograms 2Health News:Shareholder Class Action Filed Against NeuroMetrix Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Health News:Shareholder Class Action Filed Against NeuroMetrix Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Health News:Shareholder Class Action Filed Against NeuroMetrix Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 4Health News:Eminent scientists to lecture in Dallas 2Health News:Eminent scientists to lecture in Dallas 3Health News:Keynoters, symposia, workshops highlight dental research meeting 2Health News:Keynoters, symposia, workshops highlight dental research meeting 3Health News:Keynoters, symposia, workshops highlight dental research meeting 4Health News:Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 2Health News:Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 3Health News:Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 4Health News:Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference 2
Curved left, Hardy Curettes, bayonet, working distance 120 mm, total length 241 mm....
Toothed pituitary rongeur. Straight....
Micro cup pituitary forceps, semi-malleable shafts....
Teardrop dissector. 90, 5 mm....
Medicine Products: